TMCnet

CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

CREATE Medicines, Inc., ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today ...
Benzinga.com

Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects

Amgen Inc (NASDAQ:AMGN) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6). The study met its primary endpoint of overall survival ...
AASTOCKS.com

SINO BIOPHARMACEUTICAL (01177.HK)'s Vetricotobat Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Phase III Clinical Trial

SINO BIOPHARMACEUTICAL (01177.HK) announced that Vetricotobat Monoclonal Antibody (CLDN18.2 ADC), a Class 1 innovative drug ...
Benzinga.com

After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies

On Saturday, Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences Inc (NYSE:RCUS) released longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. The updated data ...
ascopubs.org

Open-label, single-arm, single-center phase 1b/2 clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive ...

Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with fluorouracil, leucovorin, and budigalimab in locally advanced/metastatic gastric, gastroesophageal junction, or esophageal ...
ascopubs.org

Phase II trial of systemic therapy plus intraperitoneal (IP) paclitaxel (PTX) in gastric/GEJ cancer peritoneal carcinomatosis (GPC): STOPGAP trial.

A multicenter phase II trial of ramucirumab plus irinotecan in patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S-1 therapy: RAMIEL trial (OGSG1901). Median PFS and ...
BioWorld

Alphamab’s HER2 bispecific hits phase III gastric cancer endpoints

Suzhou Alphamab Co. Ltd.’s HER2 bispecific antibody, anbenitamab (KN-026), combined with chemotherapy has the potential to become a new standard of care for patients with HER2-positive gastric cancer ...
Seeking Alpha

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone Bemarituzumab plus chemotherapy ...